Why Is Spyre Therapeutics (SYRE) Stock Down -13.8% Today?
Key Takeaways
- Shares fell about 13.8%, trading near $92.54 after closing the prior session at $107.36.
- The primary catalyst was a Phase 2 readout for SPY072 in rheumatoid arthritis that fell short of the company's internal bar for monotherapy development.
- Spyre will not advance SPY072 as a standalone RA treatment, but will keep exploring it in combination approaches.
- Analysts largely retained Buy/Outperform ratings, though several trimmed price targets.
- Traders are now focused on upcoming readouts in psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis.
Opening Summary
Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and other immune-mediated conditions, saw its shares slide sharply on Tuesday. The stock dropped roughly 13.8%, changing hands near $92.54 versus a prior close of $107.36. The move was driven by a single clinical catalyst: topline data from the rheumatoid arthritis (RA) arm of the company's SKYWAY Phase 2 trial, which investors judged insufficient to justify continued development of SPY072 as a standalone therapy.
SPY072 Misses the Bar in Rheumatoid Arthritis
The day's selloff stemmed from disappointing Phase 2 results for SPY072, an investigational anti-TL1A antibody, in rheumatoid arthritis. Both tested doses beat placebo and showed statistically meaningful improvements on key endpoints, but the overall effect size failed to clear the strict internal performance threshold Spyre had set to prioritize monotherapy development.
In the data, the low-dose arm posted a change from baseline in DAS28-CRP of -1.9 compared with -1.3 for placebo at week 12, while the high dose delivered a 63% ACR20 response rate versus 43% for placebo. Safety was generally clean, with adverse events reported in 27% of SPY072 participants versus 36% on placebo, most of which were mild or moderate. Still, management concluded the drug's competitive profile was not strong enough to justify a solo RA program, and the company said it will not pursue SPY072 as a monotherapy in RA.
Market Reaction and Analyst Response
The market reaction was immediate and decisive, as investors stripped out much of the value previously attributed to SPY072's RA opportunity. The stock opened near its recent highs before reversing lower through the session, reflecting disappointment that a program once seen as a potential value driver would no longer advance as a standalone treatment.
Wall Street's response was comparatively measured. Several firms reiterated bullish ratings while trimming price targets — Wedbush cut its target to $123 from $130 and BTIG to $121 from $132 — arguing that the setback does not undermine the company's core IBD combination strategy. Analysts generally framed the decline as an attractive entry point given the dense clinical calendar ahead, while acknowledging that the RA-related portion of the valuation has been largely removed from the stock.
Market Context and Trading Activity
Tuesday's decline was company-specific rather than a reflection of broad sector weakness, with the move driven almost entirely by the clinical update. Trading activity picked up meaningfully as investors repositioned around the news, and the shares retreated from levels just below their 52-week high. The pullback pushed SYRE back toward support near its recent moving averages, although the stock remains substantially higher over the past year after a prolonged rally fueled by positive ulcerative colitis data.
What Comes Next for SYRE
Despite the RA disappointment, Spyre retains a catalyst-rich pipeline. The company still expects Phase 2 readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026, along with additional ulcerative colitis data from its SKYLINE platform trial. It is also exploring SPY072 in combination settings, including the SPY772 program pairing the antibody with an IL-17A/F inhibitor for hidradenitis suppurativa.
Key risks remain: Spyre is a clinical-stage company with no approved products or commercial revenue, and its valuation leaves limited room for further clinical missteps. Investors will closely watch whether upcoming readouts validate the company's broader thesis that its antibody combinations can differentiate in IBD and related autoimmune diseases.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing traders to explore automated approaches matched to their own goals. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SYRE sees its Stochastic Oscillator ascends from oversold territory
On October 12, 2026, the Stochastic Oscillator for SYRE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 49 instances where the indicator left the oversold zone. In 45 of the 49 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 255 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SYRE as a result. In 62 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for SYRE turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.924) is normal, around the industry mean (26.782). P/E Ratio (1.716) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement